ArticleFrontiers in oncology2025
Chemotherapy as a critical treatment modality for non-surgical metaplastic breast cancer: evidence from SEER database and clinical cohort.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metaplastic breast carcinoma (MPBC) is a highly aggressive subtype of breast cancer, characterized by enhanced metastatic potential and invasive behavior. While surgery is a cornerstone of treatment, there is limited research on patients who did not undergo surgery. Methods: We conducted a retrospective analysis of non-surgical MPBC patients using data from the Surveillance, Epidemiology, and End Results (SEER) database (1975-2019). Additionally, non-surgical MPBC patients were recruited from The Third People's Hospital of Chengdu, The First Affiliated Hospital of Chongqing Medical University, and the Chongqing University Cancer Hospital to form the clinical validation cohort (2010-2024). We collected demographic and clinical data, including age, race, marital status, tumor location, and treatment modalities, etc. The primary endpoints were overall survival (OS) and breast cancer-specific survival (BCSS). Statistical analyses were performed using R software, with Kaplan-Meier curves and Cox regression models for univariate and multivariate analyses. Results: A total of 92 non-surgical MPBC patients were included from SEER database. The majority were aged≥60 years (65.22%), White (76.09%), and single (64.13%). Tumors were most frequently located in the upper quadrant (32.61%). Additionally, M1 patients were more likely to receive chemotherapy and radiotherapy compared to M0 patients (50.00% Conclusions: For MPBC patients who did not undergo surgery, chemotherapy significantly prolongs survival, highlighting its crucial role in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.